Skip to main navigation

Skip to Content

About Us
- Leadership
- Board of Directors
Our Approach
- Our Approach
- Scientific Publications
Pipeline
Investors & Media
Partnerships
Careers

Press Releases

Year

08.5.24

Terns Pharmaceuticals Reports Second Quarter 2024 Financial Results and Corporate Updates

08.1.24

Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)

07.29.24

Terns Pharmaceuticals Appoints Biotech Executive Elona Kogan as Chief Legal Officer and Announces Upcoming CFO Transition

06.21.24

Terns Pharmaceuticals Highlights New Preclinical Data Supporting TERN-501 in Combination with a GLP-1R Agonist for Obesity at the ADA’s 84th Annual Scientific Sessions and Upcoming Conference Participation

06.3.24

Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)

05.30.24

Terns Pharmaceuticals to Participate in Upcoming June Investor Conferences

05.17.24

Terns Pharmaceuticals to Participate in UBS Obesity Therapeutics Day

05.13.24

Terns Pharmaceuticals Reports First Quarter 2024 Financial Results and Corporate Updates

05.8.24

Terns Pharmaceuticals Announces Leadership Changes

05.7.24

Terns Pharmaceuticals to Participate in The Citizens JMP Life Sciences Conference 2024

First page
Previous page
Page 1
Current page 2
Page 3
Page 4
Next page
Last page

Email Alerts
RSS Feeds
Print Page
Contact IR

TERNS
1065 East Hillsdale Blvd., Suite 100
Foster City, CA 94404 (MAP)
info@ternspharma.com
investors@ternspharma.com
media@ternspharma.com
Phone: +1 650-525-5535 Ext.101
Fax: +1 650-275-4254

About Us
Our Approach
Pipeline
Investors & Media
Partnerships
Careers
Contact Us

© 2024 Terns Pharmaceuticals, Inc. Privacy Policy